Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA advisory committee
Pharma
FDA advisers back new endpoint for myeloma approvals
After experts reviewed arguments in favor of a surrogate endpoint to support approvals, myeloma drug developers may soon have a new R&D pathway.
Angus Liu
Apr 12, 2024 4:06pm
FDA review bodes well for MRD-based myeloma approvals
Apr 10, 2024 11:30am
FDA weighs another approvable myeloma endpoint. What's at stake?
Apr 9, 2024 9:00am
Novo, Novartis, Merck KGaA, Kyowa Kirin—Fierce Pharma Asia
Mar 22, 2024 8:45am
UPDATED: FDA advisers back Carvykti, Abecma in earlier myeloma
Mar 15, 2024 1:58pm
FDA flags early deaths for multiple myeloma CAR-Ts
Mar 13, 2024 11:06am